Operator: Our next question is from the line of Arthur He with H.C. Wainwright. Please proceed with your question.
Arthur He: Hey, good afternoon, gentlemen. This is Arthur on for RK. Thanks for taking my question. So, first one is regarding the Cushing business. Could you give us some color from your perspective there about the in-person clinical interactions in the second — in fourth quarter and also what you see in the first quarter this year?
Sean Maduck: Yes. No, thanks for the question. The question was what are the in-person interactions in the fourth quarter of last year and into this year. And in the past, we’ve discussed some of the obstacles that we faced because of COVID restrictions. And I’ll tell you that through the fourth quarter and today, our in-person interactions are at about 80% to 90% of pre-COVID levels. And we expect that to be our new baseline. Some previously accessible physicians closed their doors to industry during the pandemic. And I believe that some of those will keep restrictions in place permanently. So, we’re utilizing alternative means as a company to get in front of these physicians, whether it be virtual meetings, digital marketing and educational programs to try to make up some of that gap and we’ve seen some success on that.
Arthur He: Awesome. Thanks for the color. And so, regarding the ovarian cancer study, could you give us more color on enrollment status? And so far, how many sites are active for now?
Joseph Belanoff: Bill?
Bill Guyer: Probably, I’ll give you some color around there. Well, I won’t give you exact metrics on it, because we don’t really talk about metrics, but I’ll give you more color. Momentum has continued and is tracking to expectations for our ovarian cancer Phase 3 trial. We expect to fully enroll this trial by the end of this year. And we believe that because we’ve got great collaborators like the GOG, which is the Gynecological Oncology Group here in the United States and ENGOT, which is the European Network of Gynecological Oncology Trial group. Those groups are helping us get enrolled in number of sites that we need and we determine we need about 125 sites globally. And of those sites, we’ve had an investigator meeting in the United States and it was probably the most positive investigator meeting we’ve ever had, where we talked about all of the data and the investigators in the US came away with the excitement and the benefit that they saw for relacorilant that could be used in combination with nab-paclitaxel.
Next week, we’re having an investigator meeting in Europe with all of the top investigators, I think there’s about 50 investigators attending that investigator meeting, and we expect to see the same result of them seeing the same — and having the same excitement of relacorilant plus nab-paclitaxel for women in their practice. So, we expect very positive things now and moving forward to this trial.
Arthur He: Thanks so much for the color. My last question is again regarding your capital allocation strategy. With decent amount of cash, do you guys have any idea on the capital allocation? Thanks.
Joseph Belanoff: Yes. Arthur, thank you, and thank you everyone for all of your questions. Look, we have a cash producing business as we have for many, many years. And so, the exciting thing is we have very good things in Corcept in which to invest it. Our clinical programs are advancing. And as you know, as they succeed and go into later-stage studies, the programs become more expensive to do. Of course, success is a good thing. We’re very glad spend money in that way. And so, we’re really always taking a careful look at what — where our money goes. It’s not a secret we get solicited all the time from earnest investment bankers who have things that they would like us to invest in. We, of course, take a careful look at that.
